Dashboard
Manage Tickers

PTCT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ptc-therapeutics-reaffirms-fy24-financial-guidance-total-revenues-of-600m-680m-est-60663m
PTC Therapeutics Reaffirms FY24 Financial ...
04/25/2024 21:18:50

ptc-therapeutics-says-on-target-to-achieve-remaining-2024-clinical-and-regulatory-milestones-including-global-submissions-for-sepiapterin
PTC Therapeutics Says On Target To Achieve...
04/25/2024 21:16:49

ptc-therapeutics-q1-2024-gaap-eps-120-beats-129-estimate-sales-210118m-beat-169703m-estimate
PTC Therapeutics Q1 2024 GAAP EPS $(1.20) ...
04/25/2024 20:39:10

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1....

cantor-fitzgerald-reiterates-overweight-on-ptc-therapeutics-maintains-45-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/12/2024 13:55:08

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $45 price...

ptc-therapeutics-submits-sepiapterin-maa-for-treatment-of-pku-to-ema
PTC Therapeutics Submits Sepiapterin MAA F...
03/28/2024 12:34:14

- First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 -

rbc-capital-reiterates-sector-perform-on-ptc-therapeutics-maintains-28-price-target
RBC Capital Reiterates Sector Perform on P...
03/08/2024 16:35:37

RBC Capital analyst Brian Abrahams reiterates PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and maintains $28 price t...

cooper-companies-reports-upbeat-results-joins-dell-netapp-tidewater-and-other-big-stocks-moving-higher-on-friday
Cooper Companies Reports Upbeat Results, J...
03/01/2024 16:18:21

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

rbc-capital-maintains-sector-perform-on-ptc-therapeutics-raises-price-target-to-28
RBC Capital Maintains Sector Perform on PT...
03/01/2024 15:29:46

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price targe...

cantor-fitzgerald-reiterates-overweight-on-ptc-therapeutics-maintains-45-price-target
Cantor Fitzgerald Reiterates Overweight on...
03/01/2024 14:40:07

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $45 price...

td-cowen-maintains-market-perform-on-ptc-therapeutics-lowers-price-target-to-30
TD Cowen Maintains Market Perform on PTC T...
03/01/2024 13:44:26

TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Market Perform and lowers the price target fro...

ptc-therapeutics-sees-fy24-revenue-600m-680m-est-vs-612290m-est
PTC Therapeutics Sees FY24 Revenue $600M-$...
02/29/2024 21:40:28

recap-ptc-therapeutics-q4-earnings
Recap: PTC Therapeutics Q4 Earnings
02/29/2024 21:25:15

ptc-therapeutics-q4-2023-adj-eps-0240-misses-0500-estimate-sales-307056m-miss-321294m-estimate
PTC Therapeutics Q4 2023 Adj EPS $(0.240) ...
02/29/2024 21:24:51

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.240) per share which missed the analyst consensus estimate of $...

earnings-scheduled-for-february-29-2024
Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

earnings-preview-ptc-therapeutics
Earnings Preview: PTC Therapeutics
02/28/2024 18:01:04

cantor-fitzgerald-maintains-overweight-on-ptc-therapeutics-lowers-price-target-to-45
Cantor Fitzgerald Maintains Overweight on ...
01/26/2024 17:42:52

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price tar...

rbc-capital-maintains-sector-perform-on-ptc-therapeutics-lowers-price-target-to-22
RBC Capital Maintains Sector Perform on PT...
01/26/2024 15:29:06

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price targe...

ptc-therapeutics-to-withdraw-its-conditionally-approved-rare-muscle-disorder-disorder-drug-in-europe
PTC Therapeutics To Withdraw Its Condition...
01/26/2024 14:00:05

CHMP issues negative opinion on PTC Therapeutics' Translarna for Duchenne Muscular Dystrophy. CEO expresses disappointment.

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
01/26/2024 13:05:58

chmp-issues-negative-opinion-for-renewal-of-conditional-marketing-authorization-for-translarna-following-re-examination-procedure-per-european-regulations-the-european-commission-has-67-days-to-adopt-the-opinion
CHMP Issues Negative Opinion For Renewal O...
01/25/2024 21:36:20

 PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the Eur...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION